Pembrolizumab as first-line therapy in cisplatin-ineligible advanced urothelial cancer: Results from the total KEYNOTE-052 study population.

被引：24
|
作者：
Balar, Arjun Vasant
Castellano, Daniel E.
O'Donnell, Peter H.
Grivas, Petros
Vuky, Jacquiline
Powles, Thomas
机构：
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷 / 06期
关键词：
D O I：
10.1200/JCO.2017.35.6_suppl.284
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
284
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Post hoc pooled analysis of first-line (1L) pembrolizumab (pembro) for advanced urothelial carcinoma (UC): Outcomes by response at week nine in KEYNOTE-052 and KEYNOTE-361.
    Powles, Thomas
    Alva, Ajjai Shivaram
    Ozguroglu, Mustafa
    O'Donnell, Peter H.
    Loriot, Yohann
    Csoszi, Tibor
    Vuky, Jacqueline
    Morales-Barrera, Rafael
    Plimack, Elizabeth R.
    Matsubara, Nobuaki
    Fradet, Yves
    Geczi, Lajos
    Gunduz, Seyda
    Mamtani, Ronac
    Bajorin, Dean F.
    Liu, Chih-Chin
    Imai, Kentaro
    Moreno, Blanca Homet
    Bellmunt, Joaquim
    Balar, Arjun Vasant
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [22] Pembrolizumab plus either epacadostat or placebo for cisplatin-ineligible urothelial carcinoma: results from the ECHO-307/KEYNOTE-672 study
    Necchi, Andrea
    van der Heijden, Michiel S.
    Trukhin, Dmytro
    Peer, Avivit
    Gurney, Howard
    Alekseev, Boris Y.
    Parnis, Francis X.
    Leibowitz, Raya
    De Santis, Maria
    Grivas, Petros
    Clark, Jason
    Munteanu, Mihaela
    Kataria, Ritesh
    Jia, Calvin
    Balar, Arjun V.
    de Wit, Ronald
    BMC CANCER, 2024, 23 (SUPPL 1)
  • [23] Patient-Reported Outcomes in Patients With Advanced Urothelial Cancer Who Are Ineligible for Cisplatin and Treated With First-Line Enfortumab Vedotin Alone or With Pembrolizumab
    Milowsky, Matthew I.
    O'Donnell, Peter H.
    Hoimes, Christopher J.
    Petrylak, Daniel P.
    Flaig, Thomas W.
    Moon, Helen H.
    Friedlander, Terence W.
    Mar, Nataliya
    McKay, Rana R.
    Srinivas, Sandy
    Gravis, Gwenaelle
    Ramamurthy, Chethan
    Bupathi, Manojkumar
    Bracarda, Sergio
    Wright, Phoebe
    Hepp, Zsolt
    Carret, Anne-Sophie
    Yu, Yao
    Dillon, Ryan
    Kataria, Ritesh
    Beaumont, Jennifer L.
    Purnajo, Intan
    Rosenberg, Jonathan E.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (12) : 1403 - 1414
  • [24] BAYOU: Phase II study of efficacy and safety of durvalumab plus olaparib as first-line therapy in cisplatin-ineligible patients (pts) with stage iv urothelial cancer (UC)
    Rosenberg, J. E.
    Bajorin, D. F.
    Smith, A.
    D'Cruz, C.
    Lanasa, M.
    ANNALS OF ONCOLOGY, 2018, 29
  • [25] First-line (1L) enfortumab vedotin plus pembrolizumab demonstrates durable antitumour activity in cisplatin-ineligible patients with locally advanced/metastatic urothelial carcinoma (la/mUC)
    Rosenberg, J. E.
    Flaig, T. W.
    Friedlander, T. W.
    Milowsky, M. I.
    Srinivas, S.
    Petrylak, D. P.
    Merchan, J. R.
    Bilen, M. A.
    Carret, A. -S.
    Yuan, N.
    Sasse, C.
    Hoimes, C. J.
    SWISS MEDICAL WEEKLY, 2020, : 26S - 27S
  • [26] Cost-effectiveness of pembrolizumab as first-line treatment of locally advanced or metastatic urothelial carcinoma ineligible for cisplatin-based therapy in the United States.
    Lai, Yizhen
    Zhong, Yichen
    Li, Haojie
    Patterson, Karl
    Hale, Oliver
    Meng, Yang
    Frenkl, Tara L.
    Godwin, James Luke
    Mamtani, Ronac
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (27)
  • [27] Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
    Balar, Arjun V.
    Galsky, Matthew D.
    Rosenberg, Jonathan E.
    Powles, Thomas
    Petrylak, Daniel P.
    Bellmunt, Joaquim
    Loriot, Yohann
    Necchi, Andrea
    Hoffman-Censits, Jean
    Perez-Gracia, Jose Luis
    Dawson, Nancy A.
    van der Heijden, Michiel S.
    Dreicer, Robert
    Srinivas, Sandy
    Retz, Margitta M.
    Joseph, Richard W.
    Drakaki, Alexandra
    Vaishampayan, Ulka N.
    Sridhar, Srikala S.
    Quinn, David I.
    Duran, Ignacio
    Shaffer, David R.
    Eigl, Bernhard J.
    Grivas, Petros D.
    Yu, Evan Y.
    Li, Shi
    Kadel, Edward E., III
    Boyd, Zachary
    Bourgon, Richard
    Hegde, Priti S.
    Mariathasan, Sanjeev
    Thastrom, AnnChristine
    Abidoye, Oyewale O.
    Fine, Gregg D.
    Bajorin, Dean F.
    LANCET, 2017, 389 (10064): : 67 - 76
  • [28] Vinflunine/gemcitabine versus carboplatin/gemcitabine as first-line treatment in cisplatin-ineligible patients with advanced urothelial carcinoma: A randomised phase II trial (VINGEM)
    Holmsten, Karin
    Jensen, Niels Viggo
    Mouritsen, Lene Sonne
    Jonsson, Erika
    Mellnert, Camilla
    Agerbaek, Mads
    Nilsson, Cecilia
    Moe, Mette
    Carus, Andreas
    Ofverholm, Elisabeth
    Lahdenpera, Outi
    Brandberg, Yvonne
    Johansson, Hemming
    Hellstrom, Mats
    von der Maase, Hans
    Pappot, Helle
    Ullen, Anders
    EUROPEAN JOURNAL OF CANCER, 2020, 127 : 173 - 182
  • [29] Atezolizumab (atezo) in first-line cisplatin-ineligible or platinum-treated locally advanced or metastatic urothelial cancer (mUC): Long-term efficacy from phase 2 study IMvigor210
    Balar, Arjun Vasant
    Dreicer, Robert
    Loriot, Yohann
    Perez-Gracia, Jose Luis
    Hoffman-Censits, Jean H.
    Petrylak, Daniel Peter
    Van Der Heijden, Michiel Simon
    Ding, Beiying
    Shen, Xiaodong
    Rosenberg, Jonathan E.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [30] KEYNOTE-590: Phase III study of first-line chemotherapy with or without pembrolizumab for advanced esophageal cancer
    Kato, Ken
    Shah, Manish A.
    Enzinger, Peter
    Bennouna, Jaafar
    Shen, Lin
    Adenis, Antoine
    Sun, Jong-Mu
    Cho, Byoung Chul
    Ozguroglu, Mustafa
    Kojima, Takashi
    Kostorov, Vladimir
    Hierro, Cinta
    Zhu, Ying
    McLean, Lee Anne
    Shah, Sukrut
    Doi, Toshihiko
    FUTURE ONCOLOGY, 2019, 15 (10) : 1057 - 1066
12345